A Systematic Review of Aminaphtone from Pathophysiology to Clinical Applications: Focus on New Rheumatological Acquisitions
暂无分享,去创建一个
M. Cutolo | A. Sulli | C. Pizzorni | G. Pacini | S. Paolino | E. Gotelli | S. Soldano | E. Hysa
[1] F. Mendoza,et al. Ultrasound quantitative assessment of ventral finger microvasculopathy in systemic sclerosis with Raynaud’s phenomena: a comparative study , 2023, RMD Open.
[2] V. Smith,et al. Systemic sclerosis , 2022, The Lancet.
[3] M. Humbert,et al. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. , 2022, European heart journal.
[4] D. Khanna,et al. The clinical relevance of Raynaud’s phenomenon symptom characteristics in systemic sclerosis , 2022, Clinical Rheumatology.
[5] J. Wautier,et al. Vascular Permeability in Diseases , 2022, International journal of molecular sciences.
[6] J. Varga,et al. Contribution of monocytes and macrophages to the pathogenesis of systemic sclerosis: recent insights and therapeutic implications , 2021, Current opinion in rheumatology.
[7] Sahand Hamidi,et al. Causes of Raynaud's phenomenon and the predictive laboratory and capillaroscopy features for the evolution to a definite connective tissue disease. , 2021, Rheumatology.
[8] D. Khanna,et al. Factors Influencing Patient Decision‐Making Concerning Treatment Escalation in Raynaud’s Phenomenon Secondary to Systemic Sclerosis , 2021, Arthritis care & research.
[9] I. Hughes,et al. Vasodilators for primary Raynaud's phenomenon. , 2021, The Cochrane database of systematic reviews.
[10] E. Mayo-Wilson,et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews , 2021, BMJ.
[11] V. Lorenzoni,et al. Prostanoids in scleroderma microangiopathy: clinical and pharmacoeconomic comparison between two intravenous regimens , 2021, Scandinavian journal of rheumatology.
[12] M. Vonk,et al. Pulmonary hypertension in connective tissue diseases, new evidence and challenges , 2020, European journal of clinical investigation.
[13] A. Herrick,et al. Raynaud’s phenomenon , 2019, Journal of scleroderma and related disorders.
[14] A. Iagnocco,et al. Standardisation of nailfold capillaroscopy for the assessment of patients with Raynaud's phenomenon and systemic sclerosis. , 2020, Autoimmunity reviews.
[15] M. Cutolo,et al. Progression of nailfold capillaroscopic patterns and correlation with organ involvement in systemic sclerosis: a 12 year study. , 2019, Rheumatology.
[16] A. Sulli,et al. Aminaphtone Efficacy in Primary and Secondary Raynaud’s Phenomenon: A Feasibility Study , 2019, Front. Pharmacol..
[17] N. Ferrara,et al. VEGF in Signaling and Disease: Beyond Discovery and Development , 2019, Cell.
[18] T. Whayne,et al. Idiopathic "Cyclic" Edema: A Frustrating and Poorly Understood Clinical Problem. , 2019, Cardiovascular & Hematological Agents in Medicinal Chemistry.
[19] F. Felice,et al. Effect of aminaphtone on in vitro vascular permeability and capillary-like maintenance , 2018, Phlebology.
[20] M. Bertini,et al. Microcirculation and lymphedema: the role of aminaphtone , 2018, International Journal of Family & Community Medicine.
[21] J. Raffetto. Pathophysiology of Chronic Venous Disease and Venous Ulcers. , 2018, The Surgical clinics of North America.
[22] M. F. G. Guerreiro Godoy,et al. Prevalence of Idiopathic Cyclic Edema in Women with Lower Limb Lymphedema , 2017, Journal of clinical medicine.
[23] P. Tugwell,et al. Calcium channel blockers for primary and secondary Raynaud's phenomenon. , 2017, The Cochrane database of systematic reviews.
[24] M. Cutolo,et al. Assessment of treatment effects on digital ulcer and blood perfusion by laser speckle contrast analysis in a patient affected by systemic sclerosis. , 2017, Reumatismo.
[25] J. Gutermuth,et al. The role of endothelial cells in the vasculopathy of systemic sclerosis: A systematic review. , 2017, Autoimmunity reviews.
[26] C. Kayser,et al. Evaluation of the effect of sildenafil on the microvascular blood flow in patients with systemic sclerosis: a randomised, double-blind, placebo-controlled study. , 2017, Clinical and experimental rheumatology.
[27] M. Cutolo,et al. Alternatively Activated (M2) Macrophage Phenotype Is Inducible by Endothelin-1 in Cultured Human Macrophages , 2016, PloS one.
[28] R. Scorza,et al. Gene expression profiling reveals novel protective effects of Aminaphtone on ECV304 endothelial cells. , 2016, European journal of pharmacology.
[29] R. Scorza,et al. Time-course gene expression data on the transcriptional effects of Aminaphtone on ECV304 endothelial cells , 2016, Data in brief.
[30] T. Radstake,et al. Serum levels of vascular dysfunction markers reflect disease severity and stage in systemic sclerosis patients. , 2016, Rheumatology.
[31] P. Cahill,et al. Vascular endothelium - Gatekeeper of vessel health. , 2016, Atherosclerosis.
[32] D. Pollock,et al. Endothelin-1 and the kidney: new perspectives and recent findings , 2016, Current opinion in nephrology and hypertension.
[33] L. Desbiens,et al. Endothelin-1: Biosynthesis, Signaling and Vasoreactivity. , 2016, Advances in pharmacology.
[34] S. Parisi,et al. Aminaftone in the Treatment of Raynaud's Phenomenon in Systemic Sclerosis: New Perspectives , 2015 .
[35] P. Di Carlo,et al. Leg ulcer and osteomyelitis due to methicillin-susceptible Staphylococcus aureus infection after fracture repair treatment: a case highlighting the potential role of prostaglandin E₁ vasodilator. , 2015, Le infezioni in medicina : rivista periodica di eziologia, epidemiologia, diagnostica, clinica e terapia delle patologie infettive.
[36] M. Bertini,et al. Aminaphtone therapy in patients with type 1 diabetes and albuminuria: a case report , 2014, Journal of Medical Case Reports.
[37] J. M. Pereira de Godoy,et al. Aminaphtone in the control of gingival bleeding in children , 2014, Drug design, development and therapy.
[38] I. Sincos,et al. Veno-active drugs for chronic venous disease: A randomized, double-blind, placebo-controlled parallel-design trial , 2014, Phlebology.
[39] C. Martini,et al. Prevention of Excessive Endothelin-1 Release in Sclerotherapy: In Vitro and In Vivo Studies , 2014, Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.].
[40] S. Burchielli,et al. Significant Endothelin Release in Patients Treated with Foam Sclerotherapy , 2012, Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.].
[41] R. Scorza,et al. Efficacy of aminaftone in a rat model of monocrotaline-induced pulmonary hypertension. , 2011, European journal of pharmacology.
[42] J. M. Godoy,et al. Evaluation of the prevalence of concomitant idiopathic cyclic edema and cellulite. , 2011 .
[43] E. Vingolo,et al. Aminaphtone in the treatment of pseudophakic cystoid macular edema: a case report. , 2011, Clinica Terapeutica.
[44] J. M. D. de Godoy. Remission of Hypnic Headache Associated with Idiopathic Cyclic Edema with the Use of Aminaphtone , 2010, The open neurology journal.
[45] J. D. de Godoy. Treatment of stasis dermatitis using aminaphtone: a case series , 2010, Journal of medical case reports.
[46] J. M. Pereira de Godoy,et al. Aminaphtone for Light Bleeding in Patients Under Oral Anticoagulation , 2010, The open cardiovascular medicine journal.
[47] J. D. de Godoy,et al. Aminaphtone in the control of Schamberg's disease , 2009, Thrombosis journal.
[48] M. Cutolo,et al. Raynaud’s Phenomenon and Plasma Endothelin: Correlations with Capillaroscopic Patterns in Systemic Sclerosis , 2009, The Journal of Rheumatology.
[49] J. M. Pereira de Godoy. Aminaphtone in idiopathic cyclic oedema syndrome , 2008, Phlebology.
[50] R. Scorza,et al. Effects of aminaftone 75 mg TID on soluble adhesion molecules: a 12-week, randomized, open-label pilot study in patients with systemic sclerosis. , 2008, Clinical therapeutics.
[51] G. Bartolucci,et al. 3-Methyl-1,4-dioxo-1,4-dihydronaphthalen-2-yl 4-aminobenzoate , 2008, Acta crystallographica. Section E, Structure reports online.
[52] R. Scorza,et al. Aminaftone, a Derivative of 4-Aminobenzoic Acid, Downregulates Endothelin-1 Production in ECV304 Cells , 2008, Drugs in R&D.
[53] M. Coppens,et al. Calcium channel blockers for primary Raynaud's Phenomenon , 2005 .
[54] R. Barst,et al. Endothelin receptor antagonists for pulmonary arterial hypertension. , 2005, The Cochrane database of systematic reviews.
[55] X. Bonfill,et al. Phlebotonics for venous insufficiency. , 2005, The Cochrane database of systematic reviews.
[56] A Sulli,et al. Nailfold videocapillaroscopic patterns and serum autoantibodies in systemic sclerosis. , 2004, Rheumatology.
[57] V. Gasbarro,et al. [Effects of therapy with aminaftone on chronic venous and lymphatic stasis]. , 1989, Minerva cardioangiologica.
[58] P. Alfieri,et al. [Evaluation of the activity of aminaftone as coadjuvant treatment in various traumatic injuries]. , 1985, Clinica Terapeutica.